• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Regular activity may help some people stay 'fat and fit'
Conclusion As people often say, if exercise was a medicine, it would be hailed as a miracle cure. This study suggests that what we already know about the benefits of exercise may extend to reducing risk of cardiovascular disease for middle aged and older people, even if they are overweight or obese. But the study has some limitations. This type of study can't prove that one factor – exercise – is responsible for the lower risk of heart attack and stroke among overweight or obese people who exercise more. It's possible that other factors are important – for example people's income may be linked to their opportuniti...
Source: NHS News Feed - March 2, 2017 Category: Consumer Health News Tags: Obesity Lifestyle/exercise Heart/lungs Source Type: news